Abstract
Introduction: The aim of this study was to explore the role of systemic immune indices (systemic immune-inflammation index [SII] and systemic inflammatory response index [SIRI]) in the differential diagnosis between chromophobe renal cell carcinoma (chRCC) and oncocytoma. Methods: The medical records of 162 patients diagnosed with chRCC and 90 patients with oncocytoma, who underwent surgery for renal masses between January 2013 and December 2022, were reviewed. Inflammatory indices, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), SII, and SIRI, were calculated for both groups. The results were compared to assess the effects of these markers on renal cell carcinoma (RCC) subtypes. Results: Median age was significantly higher in the oncocytoma group (65 vs. 61 years, p = 0.01). Tumor size was larger in the chRCC group (p < 0.001). NLR, MLR, PLR, SII, and SIRI values were significantly higher in chRCC (all p < 0.001). ROC analysis showed area under the curve (AUC) values of 0.688 (NLR), 0.673 (MLR), 0.750 (PLR), 0.720 (SII), and 0.679 (SIRI). The optimal SII cut-off was 460 (AUC: 0.692), and for SIRI, 0.7 (AUC: 0.647), offering the best discriminative performance between chRCC and oncocytoma. Conclusion: Inflammatory indices, particularly PLR, SII, and SIRI, are accessible and cost-effective tools that can aid in the preoperative distinction of chRCC from oncocytoma, potentially guiding treatment planning.
